June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
Polypoidal choroidal vasculopathy in Caucasian patients
Author Affiliations & Notes
  • Stephen Davis
    Oregon Health and Science University, Casey Eye Institute, Portland, OR
  • Andreas Lauer
    Oregon Health and Science University, Casey Eye Institute, Portland, OR
  • Christina Flaxel
    Oregon Health and Science University, Casey Eye Institute, Portland, OR
  • Footnotes
    Commercial Relationships Stephen Davis, None; Andreas Lauer, Oxford Biomedica (F), Acucela (F), NIH (F); Christina Flaxel, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 4092. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Stephen Davis, Andreas Lauer, Christina Flaxel; Polypoidal choroidal vasculopathy in Caucasian patients. Invest. Ophthalmol. Vis. Sci. 2013;54(15):4092. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: Report on a series of Caucasian patients in the United States with Polypoidal Choroidal Vasculopathy (PCV).

Methods: Retrospective chart review of patients at a single center with PCV were identified. 24 patients were identified with an average age of 74.4 (42-89) with 13/24 (54%) being male.

Results: The most common diagnosis prior to PCV being identified was neovascular age-related macular degeneration (NVAMD) in 14/24 (58%) of patients. In only 3/24 (12.5%) was PCV the initial diagnosis. On average it took 18.4 (5-46) months before PCV was diagnosed. During this time, patients received an average of 9.3 anti-VEGF intravitreal injections. The most common reasons for suspecting PCV were the presence of a large pigment epithelial detachment (PED) in 12/24 (50%) or a poor response to anti-VEGF therapy in 12/24 (50%). Polypoidal lesions were in the macula in 19/24 (79%), the periphery in 2/24 (8%), and both the macula and periphery in 3/24 (12%). Of the polypoidal lesions in the macula, 6/19 (32%) were peripapillary and 5/19 (26%) were temporal. Of those with peripheral PCV, there were 3 cases of exudative retinal detachment, 2 of which required vitrectomy, 3 with vitreous hemorrhage, and one choroidal hemorrhage. Once PCV was diagnosed, 18/22 (81.8%) underwent photodynamic therapy (PDT), 2/22 (9%) focal laser therapy and 2/22 (9%) continued anti-VEGF monotherapy. Of those that received PDT or focal laser, the fluid and\or PED decreased in size in 18/20 (90%). An improvement in vision was seen in 7/20 (35%) with 9/20 (45%) maintaining stable vision. The follow up time after PDT or focal was 14.4 (3-46) months and during this time, patients received only an additional 2.95 anti-VEGF injections and\or 1.4 more PDT treatments on average.

Conclusions: This report is one of the larger series of PCV in an entirely Caucasian population. It contains the first report of a patient with Usher’s that developed PCV. This emphasizes the importance of PCV diagnosis in Caucasians especially if there is a poor response to anti-VEGF therapy and\or large PED present as PCV can masquerade as NVAMD. Common findings were a temporal or peripapillary location as well as the presence of lipid. It also emphasizes the importance of a peripheral exam given the risk of pathology here. In these patients, after PDT, anti-VEGF therapy was still required but the injection burden was decreased by 40% (p<0.001) and vision was improved or maintained in 80%.

Keywords: 412 age-related macular degeneration • 453 choroid: neovascularization • 452 choroid  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×